沙库巴曲缬沙坦在射血分数轻度降低或保留的心力衰竭患者中的汇总分析
该研究汇总了PARAGLIDE-HF和PARAGON-HF两项随机对照试验的参与者水平数据,评估沙库巴曲缬沙坦对比缬沙坦在射血分数轻度降低或保留的心力衰竭患者中的疗效与安全性。主要分析显示,在有近期心力衰竭恶化事件的患者中,沙库巴曲缬沙坦显著减少总心力衰竭恶化事件和心血管死亡(RR 0.78,95%CI 0.61-0.99,P=0.042),且在全部汇总人群中亦显著(RR 0.86,95%CI 0.75-0.98,P=0.027)。
要点
- 沙库巴曲缬沙坦显著降低近期心衰恶化且LVEF>40%患者的心衰事件和心血管死亡。
- 获益在LVEF≤60%的患者中更明显,交互作用P=0.021。
- 肾脏复合终点在全部汇总人群中显著降低(HR 0.60,P=0.002)。
核心结论
- 在PARAGLIDE-HF和PARAGON-HF的汇总分析中,沙库巴曲缬沙坦减少了射血分数轻度降低或保留的心力衰竭患者的心血管和肾脏事件。
研究设计与样本
- PARAGLIDE-HF和PARAGON-HF均为多中心、双盲、随机、活性对照试验,比较沙库巴曲缬沙坦与缬沙坦。
- PARAGLIDE-HF入选LVEF>40%的患者,PARAGON-HF入选LVEF≥45%的患者。
- 预先设定的主要分析汇总了PARAGLIDE-HF全部参与者(均在心衰恶化事件期间或30天内入选)与PARAGON-HF中30天内因心衰住院的“PARAGLIDE样”亚组(n=1088)。
- 还汇总了PARAGLIDE-HF和PARAGON-HF全部人群(n=5262)以提供更广泛的背景。
主要发现
- 主要汇总分析中,沙库巴曲缬沙坦对比缬沙坦显著减少总心力衰竭恶化事件和心血管死亡(RR 0.78;95%CI 0.61-0.99;P=0.042)。
- 全部参与者汇总分析中,沙库巴曲缬沙坦同样显著减少主要终点事件(RR 0.86;95%CI 0.75-0.98;P=0.027)。
- 全部参与者汇总分析中,首次名义统计学显著性在随机化后第9天达到。
- 全部参与者汇总分析中,LVEF≤60%的患者治疗获益更大(RR 0.78;95%CI 0.66-0.91),而LVEF>60%的患者无显著获益(RR 1.09;95%CI 0.86-1.40;交互作用P=0.021)。
- 肾脏复合终点在主要汇总分析中HR 0.67(95%CI 0.43-1.05;P=0.080),在全部参与者汇总分析中HR 0.60(95%CI 0.44-0.83;P=0.002)。
关键数值与推荐
- 主要终点为总心力衰竭恶化事件(包括首次和复发性心衰住院及紧急就诊)和心血管死亡的复合终点。
- 次要终点为两项研究预先设定的肾脏复合终点(估计肾小球滤过率较基线下降≥50%、终末期肾病或肾性死亡)。
临床怎么用
- 沙库巴曲缬沙坦可用于射血分数轻度降低或保留的心力衰竭患者,尤其是有近期心衰恶化事件且LVEF低于正常(≤60%)者。
- 治疗获益不依赖于诊疗场所。
局限性
- PARAGLIDE-HF本身检验临床结局的效力不足,主要分析基于与PARAGON-HF的汇总数据。
- 主要汇总分析样本量有限(n=1088),部分终点置信区间较宽。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The PARAGLIDE-HF trial demonstrated reductions in natriuretic peptides with sacubitril/valsartan compared with valsartan in patients with heart failure (HF) with mildly reduced or preserved ejection fraction who had a recent worsening HF event, but was not adequately powered to examine clinical outcomes. PARAGON-HF included a subset of PARAGLIDE-HF-like patients who were recently hospitalized for HF. Participant-level data from PARAGLIDE-HF and PARAGON-HF were pooled to better estimate the efficacy and safety of sacubitril/valsartan in reducing cardiovascular and renal events in HF with mildly reduced or preserved ejection fraction. METHODS AND RESULTS: Both PARAGLIDE-HF and PARAGON-HF were multicentre, double-blind, randomized, active-controlled trials of sacubitril/valsartan vs. valsartan in patients with HF with mildly reduced or preserved left ventricular ejection fraction (LVEF >40% in PARAGLIDE-HF and ≥45% in PARAGON-HF). In the pre-specified primary analysis, we pooled participants in PARAGLIDE-HF (all of whom were enrolled during or within 30 days of a worsening HF event) with a 'PARAGLIDE-like' subset of PARAGON-HF (those hospitalized for HF within 30 days). We also pooled the entire PARAGLIDE-HF and PARAGON-HF populations for a broader context. The primary endpoint for this analysis was the composite of total worsening HF events (including first and recurrent HF hospitalizations and urgent visits) and cardiovascular death. The secondary endpoint was the pre-specified renal composite endpoint for both studies (≥50% decline in estimated glomerular filtration rate from baseline, end-stage renal disease, or renal death). Compared with valsartan, sacubitril/valsartan significantly reduced total worsening HF events and cardiovascular death in both the primary pooled analysis of participants with recent worsening HF [n = 1088; rate ratio (RR) 0.78; 95% confidence interval (CI) 0.61-0.99; P = 0.042] and in the pooled analysis of all participants (n = 5262; RR 0.86; 95% CI: 0.75-0.98; P = 0.027). In the pooled analysis of all participants, first nominal statistical significance was reached by Day 9 after randomization, and treatment benefits were larger in those with LVEF ≤60% (RR 0.78; 95% CI 0.66-0.91) compared with those with LVEF >60% (RR 1.09; 95% CI 0.86-1.40; Pinteraction = 0.021). Sacubitril/valsartan was also associated with lower rates of the renal composite endpoint in the primary pooled analysis [hazard ratio (HR) 0.67; 95% CI 0.43-1.05; P = 0.080] and the pooled analysis of all participants (HR 0.60; 95% CI 0.44-0.83; P = 0.002). CONCLUSION: In pooled analyses of PARAGLIDE-HF and PARAGON-HF, sacubitril/valsartan reduced cardiovascular and renal events among patients with HF with mildly reduced or preserved ejection fraction. These data provide support for use of sacubitril/valsartan in patients with HF with mildly reduced or preserved ejection fraction, particularly among those with an LVEF below normal, regardless of care setting.
引用
- Vaduganathan, Mentz, Claggett, et al. Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF. Eur Heart J. 2023. PMID: 37210743. doi:10.1093/eurheartj/ehad344
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。